Abstract
Background and purpose: Cannabis is the source of at least seventy phytocannabinoids. The pharmacology of most of these has been little investigated, three notable exceptions being Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. This investigation addressed the question of whether the little-studied phytocannabinoid, cannabigerol, can activate or block any G protein-coupled receptor.
Experimental approach: The [S-35]GTP gamma S binding assay, performed with mouse brain membranes, was used to test the ability of cannabigerol to produce G protein-coupled receptor activation or blockade. Its ability to displace [H-3]CP55940 from mouse CB1 and human CB2 cannabinoid receptors and to inhibit electrically evoked contractions of the mouse isolated vas deferens was also investigated.
Key results: In the brain membrane experiments, cannabigerol behaved as a potent alpha(2)-adrenoceptor agonist (EC50 = 0.2 nM) and antagonized the 5-HT1A receptor agonist, R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (apparent K-B = 51.9 nM). At 10 mu M, it also behaved as a CB1 receptor competitive antagonist. Additionally, cannabigerol inhibited evoked contractions of the vas deferens in a manner that appeared to be alpha(2)-adrenoceptor-mediated (EC50 = 72.8 nM) and displayed significant affinity for mouse CB1 and human CB2 receptors.
Conclusions and implications: This investigation has provided the first evidence that cannabigerol can activate alpha(2)-adrenoceptors, bind to cannabinoid CB1 and CB2 receptors and block CB1 and 5-HT1A receptors. It will now be important to investigate why cannabigerol produced signs of agonism more potently in the [S-35]GTP gamma S binding assay than in the vas deferens and also whether it can inhibit noradrenaline uptake in this isolated tissue and in the brain. British Journal of Pharmacology (2010) 159, 129-141; doi:10.1111/j.1476-5381.2009.00515.x; published online 4 December 2009
Original language | English |
---|---|
Pages (from-to) | 129-141 |
Number of pages | 13 |
Journal | British Journal of Pharmacology |
Volume | 159 |
Issue number | 1 |
Early online date | 4 Dec 2009 |
DOIs | |
Publication status | Published - Jan 2010 |
Keywords
- cannabigerol
- CP55940
- mouse vas deferens
- alpha(2)-adrenoceptor
- 5-HT1A receptor
- CB1 receptor
- clonidine
- dexmedetomidine
- maprotiline
- R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin
- mouse vas-deferens
- pharmacological profile
- CB1
- noradrenaline
- hashish
- release
- Delta(9)-tetrahydrocannabivarin
- adrenoceptors
- constituents
- cannabidiol
- cannabigerol
- CP55940
- mouse vas deferens
- a2-adrenoceptor
- 5-HT1A receptor
- CB1 receptor
- clonidine
- maprotiline
Fingerprint
Dive into the research topics of 'Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist'. Together they form a unique fingerprint.Impacts
-
Cannabis as a source of medicines
Roger Pertwee (Coordinator), P Consroe (Coordinator), R Musty (Coordinator) & David Baker (Coordinator)
Impact: Health and Wellbeing